Searched for
ASTRAZENECA ENHERTU
AstraZeneca's Enhertu gets regulatory approval in India for first-line HER2-positive breast cancerAstraZeneca Pharma India has secured approval from India's drug regulator for its smart chemotherapy drug Enhertu. This allows for its impo...- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- GSK's antibiotic drug Augmentin is India's highest-selling brand with Rs 80 crore monthly saleEnhertu, a cancer drug by AstraZeneca, was the top-selling new drug in 2024 with sales of nearly Rs 58 crore. Over 3,100 new brands were la...
- Over 3k brands hit pharma mkt, cancer drug tops in salesIndia's pharma market has introduced 3,151 new brands in the past year, with AstraZeneca's cancer drug Enhertu becoming the top-seller, ref...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- Daiichi Sankyo, Merck ink $22-billion cancer drug dealThe deal adds promising drug candidates to Merck's oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expir...
- 'Unheard-of' cancer drug trials slow tumor growth, extend life of patientsThe new study would change how medicine was practiced, cancer specialists said.
- AstraZeneca to acquire Alexion in $39 billion dealAlexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share.
Load More